These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 33497525)

  • 1. Sacubitril/valsartan ameliorates cardiac hypertrophy and preserves diastolic function in cardiac pressure overload.
    Nordén ES; Bendiksen BA; Andresen H; Bergo KK; Espe EK; Hasic A; Hauge-Iversen IM; Veras I; Hussain RI; Sjaastad I; Christensen G; Cataliotti A
    ESC Heart Fail; 2021 Apr; 8(2):918-927. PubMed ID: 33497525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sacubitril/valsartan attenuates myocardial inflammation, hypertrophy, and fibrosis in rats with heart failure with preserved ejection fraction.
    Shi YJ; Yang CG; Qiao WB; Liu YC; Liu SY; Dong GJ
    Eur J Pharmacol; 2023 Dec; 961():176170. PubMed ID: 37939991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sacubitril/valsartan inhibits obesity-associated diastolic dysfunction through suppression of ventricular-vascular stiffness.
    Aroor AR; Mummidi S; Lopez-Alvarenga JC; Das N; Habibi J; Jia G; Lastra G; Chandrasekar B; DeMarco VG
    Cardiovasc Diabetol; 2021 Apr; 20(1):80. PubMed ID: 33882908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sacubitril/Valsartan Improves Diastolic Function But Not Skeletal Muscle Function in a Rat Model of HFpEF.
    Schauer A; Adams V; Augstein A; Jannasch A; Draskowski R; Kirchhoff V; Goto K; Mittag J; Galli R; Männel A; Barthel P; Linke A; Winzer EB
    Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33808232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of sacubitril/valsartan on cardiac function in heart failure rabbits with preserved ejection fraction].
    Gao SY; Yao DH; Li JF; Xie QM; Jiang SC
    Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Nov; 47(11):887-893. PubMed ID: 31744278
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of sacubitril/valsartan on the hypertensive heart in continuous light-induced and lactacystin-induced pre-hypertension: Interactions with the renin-angiotensin-aldosterone system.
    Simko F; Stanko P; Repova K; Baka T; Krajcirovicova K; Aziriova S; Domenig O; Zorad S; Adamcova M; Paulis L
    Biomed Pharmacother; 2024 Apr; 173():116391. PubMed ID: 38461685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study on the Efficacy of Sacubitril/Valsartan in Patients with Heart Failure with Preserved Ejection Fraction Undergoing Peritoneal Dialysis.
    Sheng Y; Ma X; Liu Y; Yang X; Sun F
    Cardiology; 2023; 148(5):385-394. PubMed ID: 37253340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sacubitril/valsartan mitigates cardiac remodeling, systolic dysfunction, and preserves mitochondrial quality in a rat model of mitral regurgitation.
    Tantisuwat L; Saengklub N; Boonpala P; Kumphune S; Panyasing Y; Kalandakanond-Thongsong S; Kijtawornrat A
    Sci Rep; 2023 Jul; 13(1):11472. PubMed ID: 37455281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The benefits of the earlier use of sacubitril/valsartan in de novo heart failure with reduced ejection fraction patients.
    Oh JH; Lee JM; Lee HJ; Hwang J; Lee CH; Cho YK; Park HS; Yoon HJ; Chung JW; Kim H; Nam CW; Han S; Hur SH; Youn JC; Kim IC
    ESC Heart Fail; 2022 Aug; 9(4):2435-2444. PubMed ID: 35484930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sacubitril/Valsartan Decreases Cardiac Fibrosis in Left Ventricle Pressure Overload by Restoring PKG Signaling in Cardiac Fibroblasts.
    Burke RM; Lighthouse JK; Mickelsen DM; Small EM
    Circ Heart Fail; 2019 Apr; 12(4):e005565. PubMed ID: 30998392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sacubitril/Valsartan Averts Adverse Post-Infarction Ventricular Remodeling and Preserves Systolic Function in Rabbits.
    Torrado J; Cain C; Mauro AG; Romeo F; Ockaili R; Chau VQ; Nestler JA; Devarakonda T; Ghosh S; Das A; Salloum FN
    J Am Coll Cardiol; 2018 Nov; 72(19):2342-2356. PubMed ID: 30384891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sacubitril/Valsartan Improves Left Ventricular Function in Chronic Pressure Overload Independent of Intact Cyclic Guanosine Monophosphate-dependent Protein Kinase I Alpha Signaling.
    Tam K; Richards DA; Aronovitz MJ; Martin GL; Pande S; Jaffe IZ; Blanton RM
    J Card Fail; 2020 Sep; 26(9):769-775. PubMed ID: 32464187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined Angiotensin Receptor-Neprilysin Inhibitors Improve Cardiac and Vascular Function Via Increased NO Bioavailability in Heart Failure.
    Trivedi RK; Polhemus DJ; Li Z; Yoo D; Koiwaya H; Scarborough A; Goodchild TT; Lefer DJ
    J Am Heart Assoc; 2018 Mar; 7(5):. PubMed ID: 29502102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early experience of Sacubitril-Valsartan in heart failure with reduced ejection fraction in real-world clinical setting.
    Nordberg Backelin C; Fu M; Ljungman C
    ESC Heart Fail; 2020 Jun; 7(3):1049-1055. PubMed ID: 32030899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiometabolic effects of sacubitril/valsartan in a rat model of heart failure with preserved ejection fraction.
    Moraña-Fernández S; Vázquez-Abuín X; Aragón-Herrera A; Anido-Varela L; García-Seara J; Otero-García Ó; Rodríguez-Penas D; Campos-Toimil M; Otero-Santiago M; Rodrigues A; Gonçalves A; Pereira Morais J; Alves IN; Sousa-Mendes C; Falcão-Pires I; González-Juanatey JR; Feijóo-Bandín S; Lago F
    Biochem Pharmacol; 2024 Dec; 230(Pt 1):116571. PubMed ID: 39424202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sacubitril/valsartan treatment has differential effects in modulating diabetic kidney disease in
    Myakala K; Jones BA; Wang XX; Levi M
    Am J Physiol Renal Physiol; 2021 Jun; 320(6):F1133-F1151. PubMed ID: 33870733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and safety evaluation of sacubitril/valsartan in blood pressure control and clinical outcomes for elderly patients with heart failure and hypertension: A prospective cohort study.
    Li X; Zuo C; Chen C; Tian D; Li J; Fan L; Li X; Lv Q
    Int J Cardiol; 2023 Jan; 371():244-251. PubMed ID: 36174825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LCZ696 (Sacubitril/Valsartan), an Angiotensin-Receptor Neprilysin Inhibitor, Attenuates Cardiac Hypertrophy, Fibrosis, and Vasculopathy in a Rat Model of Chronic Kidney Disease.
    Suematsu Y; Jing W; Nunes A; Kashyap ML; Khazaeli M; Vaziri ND; Moradi H
    J Card Fail; 2018 Apr; 24(4):266-275. PubMed ID: 29325796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined levosimendan and Sacubitril/Valsartan markedly protected the heart and kidney against cardiorenal syndrome in rat.
    Sung PH; Chai HT; Yang CC; Chiang JY; Chen CH; Chen YL; Yip HK
    Biomed Pharmacother; 2022 Apr; 148():112745. PubMed ID: 35202913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardioprotective effects of early intervention with sacubitril/valsartan on pressure overloaded rat hearts.
    Li X; Braza J; Mende U; Choudhary G; Zhang P
    Sci Rep; 2021 Aug; 11(1):16542. PubMed ID: 34400686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.